MX2022010360A - Anticuerpos y receptores de antígenos quiméricos dirigidos a glipicano-3 (gpc3) y métodos para usarlos. - Google Patents

Anticuerpos y receptores de antígenos quiméricos dirigidos a glipicano-3 (gpc3) y métodos para usarlos.

Info

Publication number
MX2022010360A
MX2022010360A MX2022010360A MX2022010360A MX2022010360A MX 2022010360 A MX2022010360 A MX 2022010360A MX 2022010360 A MX2022010360 A MX 2022010360A MX 2022010360 A MX2022010360 A MX 2022010360A MX 2022010360 A MX2022010360 A MX 2022010360A
Authority
MX
Mexico
Prior art keywords
gpc3
antibodies
chimeric antigen
methods
glypican
Prior art date
Application number
MX2022010360A
Other languages
English (en)
Spanish (es)
Inventor
Xiaohu Fan
Qiuchuan Zhuang
Jie Mao
Ruixue Wang
Original Assignee
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotech Co Ltd filed Critical Nanjing Legend Biotech Co Ltd
Publication of MX2022010360A publication Critical patent/MX2022010360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
MX2022010360A 2020-02-27 2021-02-26 Anticuerpos y receptores de antígenos quiméricos dirigidos a glipicano-3 (gpc3) y métodos para usarlos. MX2022010360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020076937 2020-02-27
PCT/CN2021/078203 WO2021170100A1 (en) 2020-02-27 2021-02-26 Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022010360A true MX2022010360A (es) 2022-09-21

Family

ID=77490732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010360A MX2022010360A (es) 2020-02-27 2021-02-26 Anticuerpos y receptores de antígenos quiméricos dirigidos a glipicano-3 (gpc3) y métodos para usarlos.

Country Status (12)

Country Link
US (1) US20230088461A1 (https=)
EP (1) EP4110912A4 (https=)
JP (1) JP7747645B2 (https=)
KR (1) KR20220146456A (https=)
CN (1) CN115151639A (https=)
AU (1) AU2021225978A1 (https=)
BR (1) BR112022016958A2 (https=)
CA (1) CA3170023A1 (https=)
IL (1) IL295774A (https=)
MX (1) MX2022010360A (https=)
WO (1) WO2021170100A1 (https=)
ZA (1) ZA202209069B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230147619A (ko) * 2021-02-26 2023-10-23 난징 레전드 바이오테크 씨오., 엘티디. 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포
WO2024022509A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Methods for promoting persistence of cell therapy
US20260027209A1 (en) * 2022-07-29 2026-01-29 Legend Biotech Ireland Limited Claudin-6 binding moieties and uses thereof
CN117025541B (zh) * 2023-08-15 2025-10-17 福建医科大学附属协和医院 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途
WO2025159562A1 (ko) * 2024-01-24 2025-07-31 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050020806A (ko) * 2002-05-23 2005-03-04 써니브룩 앤드 우먼스 칼리지 헬스 사이언시즈 센터 간세포암의 진단
EP1684076B1 (en) * 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
JP2017529851A (ja) * 2014-09-26 2017-10-12 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター
ES2818103T3 (es) * 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
JP2019532953A (ja) * 2016-09-30 2019-11-14 ノバルティス アーゲー 増強された有効性を有する免疫エフェクター細胞治療
MX2019008221A (es) * 2017-01-10 2019-12-09 Univ Yamaguchi Anticuerpo anti-gpc3.
EP3615574A4 (en) * 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
WO2020017479A1 (ja) * 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
CN110684120B (zh) * 2019-10-12 2023-03-07 华夏源（上海）细胞基因工程股份有限公司 一种靶向gpc3的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
US20230088461A1 (en) 2023-03-23
CN115151639A (zh) 2022-10-04
CA3170023A1 (en) 2021-09-02
IL295774A (en) 2022-10-01
ZA202209069B (en) 2023-10-25
EP4110912A1 (en) 2023-01-04
WO2021170100A1 (en) 2021-09-02
JP2023516286A (ja) 2023-04-19
JP7747645B2 (ja) 2025-10-01
AU2021225978A1 (en) 2022-09-08
EP4110912A4 (en) 2024-07-10
BR112022016958A2 (pt) 2022-10-25
KR20220146456A (ko) 2022-11-01

Similar Documents

Publication Publication Date Title
ZA202209069B (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
ZA202206438B (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
WO2020016662A3 (en) Antibodies specific to trophoblast antigen 2 (trop2)
AU2018449846A8 (en) An anti-B7-H3 antibody
NZ789779A (en) Lilrb1-based chimeric antigen receptor
MX2019011526A (es) Receptores de union a antigeno mejorados.
EP4424376A3 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12019502411A1 (en) Cells expressing chimeric activitaing receptors and chimeric stimulating receptors and uses thereof
WO2017130223A3 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
EP4549554A3 (en) Reagents for expanding cells expressing recombinant receptors
RU2011129794A (ru) Ковалентные диантитела и их применение
TR201910814T4 (tr) Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
WO2019090003A8 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
WO2019155286A3 (en) Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy
PH12022551470A1 (en) Materials and methods for in vivo biological targeting
JP2013540696A5 (https=)
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
WO2008138536A3 (en) Antibody directed to g protein coupled receptors (gpcr)
WO2022115641A3 (en) Antigen specific t cells and methods of making and using same
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
WO2022164886A3 (en) Chimeric antigen receptors targeting cd20
MX2025008002A (es) Construcciones de anticuerpos específicos para el cúmulo de diferenciación 19 (cd19) y composiciones de estos